Nasus Pharma
Manufacturing · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
65 Yigal Alon, Tel Aviv, IsraelPhone Number
+972 35736632Website
www.nasuspharma.comRevenue
-Stock Symbol
NSRXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Nasus Pharma
Nasus Pharma specializes in developing a portfolio of powder-based intranasal products aimed at addressing acute medical conditions and public health threats. Utilizing unique microsphere technology, their products provide rapid absorption and quick drug delivery, making them suitable for emergency situations. Their intranasal therapies, including Naloxone and Epinephrine, excel in speed and effectiveness, potentially saving lives. The company targets healthcare providers and emergency response systems that require efficient drug delivery solutions in critical moments.Explore more
Nasus Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nasus Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Nasus Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Nasus Pharma
Click to see if Nasus Pharma had a recent Job posting/layoffs
Check out if Nasus Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nasus Pharma has recently received funding, and reach out quickly before it becomes old news!
Nasus Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Nasus Pharma has new funding data
Product Launch: Get notified when Nasus Pharma launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Nasus Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nasus Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nasus Pharma.
Nasus Pharma financials insights
Gather financial insights about Nasus Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$15M
Nasus Pharma Tech Stack
A closer look at the technologies used by Nasus Pharma
See more technologies
Nasus Pharma News & Media
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 10, 2026 at 8:00 AM ET featuring Michael S. Blaiss, MD (Medical College of Georgia, Good Samaritan Health Center of Gwinnett) and Joel Brooks, DO, MPH (Columbia UniversityNasus Pharma to Participate in Upcoming Investor Conferences
TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences.Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nasus Pharma
Sign Up For FreeTo access detailed company insights
Nasus Pharma specializes in developing a portfolio of powder-based intranasal products aimed at addressing acute medical conditions and public health threats. Utilizing unique microsphere technology, their products provide rapid absorption and quick drug delivery, making them suitable for emergency situations. Their intranasal therapies, including... Read More
